China Capabilities


Being a Pioneer means trial and error. Benefit from an experienced partner.


we have a great working relationship with both the NMPA and HGR. This is critically important in China.

Scientific Soundness

The great scientific rationale is the basis of every successful trial.

Pioneers of the Chinese Market

Burning Rock is the NGS Market leader in China with a 27% overall market share. We received the first-ever NMPA approved CDx NGS oncology panel in 2018 and the project received the first ctDNA approval as well as the first TMB panel approval.

China's commercial and regulatory environment has proven to be one of the most difficult regions in the world. We are seeing that the Chinese precision oncology market is growing exponentially and is projected to reach 40 B by 2030.

There is much confusion on the best strategy and best practices of how to commercialize a precision oncology therapeutic, how to run clinical trials, and assay reimbursement as well as legality.

It is also extremely difficult to get the required data, results, reports from patients in China, and Biosample export restrictions are extremely stringent.

Overall Coverage Network


Cumulative Number of Referring Hospitals


Sales Representatives


Overall Market Share

In Hospital Channel

Integrate Genomic and Clinical Databases
Design Labs
Build-up NGS Platforms
Customize Lab SOPs and Reports
Train Hospital Staff




Market Share

We Can Help With

Overcoming challenges of running Clinical Trials in China and implications for global trials.
Data Sharing, HGRAC Approval, Changes to new CDx Indication.
Clinical Biomarker work, how to get your studies approved.
Regulatory approval (NMPA, HGRAC, NCCL).
Commercial launch, reimbursement, considerations for Day 1 assay availability.

Let Us Be Your Launchpad Into China

Burning Rock has a history of firsts in China and we are the NGS market leader


First NMPA (CFDA) approved IVD
NGS Panel (2018)

First Co-Development of CDx and Drug

Collaboration with Cstone Pharmaceuticals is the first case of Drug and CDx co-development in the history of NMPA

First Projected ctDNA & TMB Approval

First projected liquid biopsy panel
approval in China as well as the
first projected approval for TMB
(IO Biomarkers)